THE LONDON GAZETTE, DECEMBER. Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations with intelligence they can trust to transform their world, today announced the launch of VeriSIM Life Translational IndexTM on Cortellis Drug Discovery Intelligence by Clarivate, a global leader in connecting people and organizations to intelligence they can trust to transform their world.. With this integrated workflow, customers are provided with a diverse range of predictive compound safety and efficacy insights, including bioavailability, hepatic and renal clearance, clinical toxicity, first-in-human dose, and much more.
With this integrated workflow, customers are provided with a diverse range of predictive compound safety and efficacy insights, including bioavailability, hepatic and renal clearance, clinical toxicity, first-in-human dose, and much more.
A new solution offering serves as the next phase of the expanding partnership between Clarivate and VeriSIM Life, a leader in artificial intelligence (AI)-enabled, R&D decision de-riskers for breakthrough drug development, which was announced earlier this year.
As Robert Poolman, Senior Vice President of Life Sciences and Healthcare Products at Clarivate, said: “As emerging technology continues to evolve to meet the growing needs of biotechs, pharmaceutical companies, and patients alike, drug developers can use artificial intelligence to reduce the time it takes for research and development, increase the number of clinically active compound candidates, while staying in compliance with government regulations and standards in the process.. In partnership with VeriSIM Life, the Translational Index for Clarivate leverages artificial intelligence to address these unmet needs, improving pre-clinical success rates, and ultimately equipping our customers with the insight and foresight they need to create innovative treatments, get them to patients more quickly, and help create a healthier tomorrow.
In partnership with VeriSIM Life, the Translational Index for Clarivate leverages artificial intelligence to address these unmet needs, improving pre-clinical success rates, and ultimately equipping our customers with the insight and foresight they need to create innovative treatments, get them to patients more quickly, and help create a healthier tomorrow.
According to Jo Varshney, CEO & Founder of VeriSIM Life, "the science of translating medicinal candidates into safe and effective therapies is extremely complex,". It is common knowledge that researchers need solutions that complement their workflows and scientific methods while improving the likelihood of a successful clinical trial. We are extending our integration with Clarivate as a natural evolution for scientific discovery within research organizations in order to advance the next generation of life saving medicines through the integration of Clarivate. Additionally, it allows the owners of drug programs to manage the risk of asset development in a more effective manner.
Additionally, it allows the owners of drug programs to manage the risk of asset development in a more effective manner.
It has been deemed "unsustainable" for the pharmaceutical industry by the FDA that translating drug candidates into successful clinical trial outcomes is a time consuming and costly process. It is imperative that pharmaceutical and biopharma companies optimize their tools to efficiently translate data into insights that can accelerate the development of drugs, as they need accurate objective data and predictive analytics to enable informed decision-making.

Source prnewswire